Yu'e Zhang

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

Zhaoli Liu, Shuangyou Liu, B. Deng, 2021, Molecular therapy. Methods & clinical development.

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial

Xudong Zhang, Qiming Wang, Tianjiang Ma, 2021, Translational lung cancer research.

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

Jin Gao, Xuan Zhou, Zhaoli Liu, 2019, Leukemia.

Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Zhaoli Liu, P. Lu, B. Deng, 2016 .

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

Jin Gao, Xuan Zhou, Zhaoli Liu, 2019, Leukemia.